Non-Hodgkin's Lymphoma Clinical Trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 127 clinical trials
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

cyclin d1
bendamustine
rituximab
acalabrutinib
  • 1279 views
  • 17 Sep, 2021
  • 253 locations
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma

chronic lymphocytic leukemia
b-cell lymphoma
leukemia
beta human chorionic gonadotrophin
lymphoma
  • 82 views
  • 15 Sep, 2021
  • 55 locations
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the RP2D(s) in Part B.

b-cell lymphoma
marginal zone lymphoma
lymphoma
tyrosine
measurable disease
  • 1 views
  • 16 Sep, 2021
  • 36 locations
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). For pediatric

b-cell lymphoma
measurable disease
blood transfusion
gilbert's syndrome
hodgkin's disease
  • 6 views
  • 18 Sep, 2021
  • 37 locations
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

  • 40 views
  • 10 Sep, 2021
  • 122 locations
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

This is a Phase 3 study of the PI3K inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

bendamustine
cyclophosphamide
prednisone
measurable disease
chop regimen
  • 0 views
  • 19 Sep, 2021
  • 8 locations
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the

chronic lymphocytic leukemia
leukemia
beta human chorionic gonadotrophin
lymphoma
lymphoid leukemia
  • 25 views
  • 16 Sep, 2021
  • 17 locations
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin

chronic lymphocytic leukemia
leukemia
lymphoma
  • 0 views
  • 16 Sep, 2021
  • 33 locations
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Multiple Myeloma)

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin

b-cell lymphoma
lymphoma
refractory non-hodgkin's lymphoma
multiple myeloma
tumor cells
  • 0 views
  • 17 Sep, 2021
  • 4 locations
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.

kinase inhibitor
taxane
breast cancer
mek inhibitor
bladder cancer
  • 230 views
  • 19 Sep, 2021
  • 28 locations